ArticleDiscover nano2026
Comparative characterization and anti Helicobacter pylori activity of green synthesized silver nanoparticles from red and yellow fruited Ficus carica L. leaf extracts.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundGreen synthesis of silver nanoparticles (AgNPs) using plant extracts offers an eco-friendly and sustainable approach for developing novel antimicrobial agents. Ficus carica L. leaf extract (FcLE), rich in bioactive phytochemicals, has potential as a natural reducing and stabilizing agent. This study aimed to comparatively evaluate AgNPs synthesized from yellow- and red-fruited F. carica L. leaf extracts and assess their antibacterial activity against Helicobacter pylori.
resultsFcLE exhibited strong bioreduction capability, likely mediated by the transformation of phytochemicals (catechin, myricetin, and epigallocatechin gallate) into oxidized derivatives acting as reducing and capping agents. Optimal synthesis conditions were identified at 1% (v/v), 50 °C, and neutral pH, ensuring nanoparticle stability and preventing agglomeration. Morphological characterization revealed distinct differences, with yellow-fruited FcLE producing monodisperse, spherical AgNPs (average diameter 3.87 nm) with a narrow size distribution, whereas red-fruited FcLE generated larger, clustered particles (~ 40-50 nm). X-ray diffraction confirmed a crystalline biphasic silver/silver oxide structure, with higher metallic silver phase purity (60%) in yellow-fruited FcLE-AgNPs. Zeta potential values (up to - 50 mV) indicated strong colloidal stability due to electrostatic repulsion. Antibacterial assays demonstrated moderate inhibition against Escherichia coli and Staphylococcus aureus (11 ± 0.6 mm and 10 ± 0.5 mm, respectively). Against H. pylori, yellow- and red-fruited FcLE-AgNPs produced mean inhibition zones of 20.00 ± 0.00 mm and 18.33 ± 0.58 mm, respectively, whereas the crude leaf extract showed no antibacterial activity under the tested conditions. Tetracycline produced a larger inhibition zone (49 mm) and served as the positive control. In silico docking further suggested that FcLE-derived compounds may interact with the urease enzyme.
conclusionsThese findings demonstrate that FcLE phytochemicals enable efficient synthesis of stable AgNPs at low concentrations and contribute to enhanced antibacterial activity. The synthesized nanoparticles exhibit promising In vitro antibacterial activity against H. pylori and warrant further investigation as plant-mediated nanomaterials for the management of H. pylori-associated gastric infections.
Indexed as
Identifiers
42879063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.